Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PHIBEST: Pinaverium and Tong Xie Yao Fang for IBS
NCT02330029Unknown
- Sponsor
- Macrohard Institute of Health
- Start
- Aug 2012
- Primary completion
- Nov 2014
- Modality
- Implantable Devices, Transdermal Patches, Inhalation Devices
- Countries
- 1
01
Overview
Randomised, double-blind trial of pinaverium and tongxieyaofang in irritable bowel syndrome (IBS) (3 arms), sponsored by Macrohard Institute of Health. Primary endpoints: Abdominal pain at 2 years and Form (appearance) of stool at 2 years. Status: unknown.
02
Drugs
pinaveriumtongxieyaofang
03
Conditions
irritable bowel syndrome (IBS)
Beyond the preview
Go deeper on NCT02330029.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02330029.